Literature DB >> 1958004

Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions.

P B Daly1, J H Evans, R H Kobayashi, A L Kobayashi, H D Ochs, S H Fischer, B Pirofsky, C Sprouse.   

Abstract

Thirty-seven antibody-deficient patients who were participating in a multicenter trial evaluating home-based, self-administered IVIG therapy anonymously completed questionnaires regarding beliefs concerning health control, quality of life, and attitudes toward active participation in medical care. Their responses were compared with a group of 29 patients undergoing traditional IVIG therapy in a medical clinic setting. A subsample of the home-based group who later returned to clinic-based IVIG therapy allowed comparison of responses given by the same patients in both settings. Home-based therapy was preferred to clinic-based therapy. Independence, convenience, comfort, decreased disruption of activities, travel time, and costs were specific factors rated most favorably. On the Health Belief Questionnaires, patients preferred informed, self-involved medical care regardless of the setting for their IVIG treatments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958004

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  23 in total

Review 1.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

2.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 4.  Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors:  Richard L Wasserman
Journal:  J Clin Immunol       Date:  2012-07-25       Impact factor: 8.317

5.  Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.

Authors:  Serge Sultan; Émélie Rondeau; Marie-Claude Levasseur; Renée Dicaire; Hélène Decaluwe; Élie Haddad
Journal:  J Clin Immunol       Date:  2017-06-08       Impact factor: 8.317

Review 6.  Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.

Authors:  D Nathwani
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 7.  Clinical immunology in practice, new opportunities.

Authors:  Mark R Stein
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

8.  Health related quality of life in common variable immunodeficiency.

Authors:  Isabella Quinti; Cristina Di Pietro; Helene Martini; Anna Maria Pesce; Francesca Lombardi; Maddalena Baumghartner; Stefania Colantuono; Cinzia Milito; Stefano Tabolli
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

Review 9.  C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.

Authors:  H J Longhurst; S Carr; K Khair
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 10.  Health-related quality of life in patients with primary immunodeficiency disease.

Authors:  Fonda Jiang; Troy R Torgerson; Andrew G Ayars
Journal:  Allergy Asthma Clin Immunol       Date:  2015-09-29       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.